drugset / Trial / NCT06514898

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

NCT06514898

NaSingle-groupOpen-labelTreatment

Summary

This is a pilot study in a small number of children and young adults with suspected recurrent/progressive medulloblastoma (MB) looking at the feasibility and safety of adoptive cell therapy plus PD-1 blockade.

Timeline

Start
2025-05-05
Primary completion
2027-09-01
Completion
2028-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody Intravenous
Subject TTRNA-DC vaccines Vaccine Other
Subject TTRNA-xALT Cell therapy Intravenous
Background Td vaccine Vaccine 1 unknown Intramuscular
Background Td vaccine Vaccine 5 unknown Intramuscular
Background autologous HSCs Cell therapy 2 unknown Intravenous
Background sargramostim Protein / enzyme biologic 150 ug Other